The role of sub-retinal fluid in determining treatment outcomes in patients with neovascular age-related macular degeneration - a phase IV randomised clinical trial with ranibizumab: the FLUID study

BACKGROUND: With increasing experience using anti-VEGF therapy for the treatment of neovascular age-related macular degeneration (nAMD), ophthalmologists have shifted away from a “one size fits all” to an “individualised” approach based on disease activity with the aim of achieving a fluid-free reti...

Descripción completa

Detalles Bibliográficos
Autores principales: Arnold, Jennifer J., Markey, Caroline M., Kurstjens, Nicol P., Guymer, Robyn H.
Formato: Online Artículo Texto
Lenguaje:English
Publicado: BioMed Central 2016
Materias:
Study Protocol
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4806513/
https://www.ncbi.nlm.nih.gov/pubmed/27009515
http://dx.doi.org/10.1186/s12886-016-0207-3

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4806513/
https://www.ncbi.nlm.nih.gov/pubmed/27009515
http://dx.doi.org/10.1186/s12886-016-0207-3

Ejemplares similares